Business Context and Reporting Period
Company: Wearable Devices Ltd. (WLDS)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: An Israeli growth company developing non-invasive neural input interfaces (Surface Nerve Conductance or SNC) for wearable devices. The company operates a B2B model (licensing technology to electronics manufacturers) and a B2C model (selling the "Mudra Band" for Apple Watch and the "Mudra Link" universal wristband).
Corporate Actions: The company executed a 1-for-20 reverse share split in October 2024 and a 1-for-4 reverse share split in March 2025 to maintain Nasdaq listing compliance. All historical data is presented on a post-split basis.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (USD '000s) | 2023 (USD '000s) |
|---|---|---|
| Revenues | $522 | $82 |
| Cost of Revenues | $(437) | $(62) |
| Gross Profit | $85 | $20 |
| Operating Loss | $(7,820) | $(8,186) |
| Net Loss | $(7,879) | $(7,814) |
| Cash and Cash Equivalents | $3,089 | $810 |
| Accumulated Deficit | $(29,102) | $(21,223) |
| Shareholders' Equity | $3,860 | $5,526 |
Liquidity: Net cash used in operating activities was $7.6 million. Net cash provided by financing activities was $6.7 million, driven by share issuances under a Standby Equity Purchase Agreement (SEPA) and registered direct offerings. Management believes existing cash will support operations through September 2025.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 537% to $522,000, primarily driven by the commercialization and sales of the B2C Mudra Band.
- Cost Structure: Cost of revenues increased 600% to $437,000 due to higher manufacturing costs associated with increased B2C sales volume.
- R&D Expenses: Decreased 11% to $2.96 million due to reduced labor, materials, and subcontractor costs as the company transitions from development to production, partially offset by a decrease in Israeli Innovation Authority (IIA) grant participation.
- Financing Activity: Significant capital raises occurred in 2024, including proceeds from the SEPA ($4.4 million net) and a registered direct offering ($1.58 million net), compared to a public offering in 2023.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The financial statements include an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses and dependence on external financing. The company has incurred accumulated losses of $29.1 million.
Outlook: The company expects to continue generating substantial operating losses. Future capital needs will be met through equity issuances, debt, or government grants. There is no assurance that financing will be available on acceptable terms.
Key Risks:
- Nasdaq Compliance: The company received a notification in January 2025 regarding non-compliance with the minimum stockholders' equity requirement ($2.5 million). A plan to regain compliance has been submitted.
- Geopolitical Instability: Operations are based in Israel. Ongoing conflicts (Hamas, Hezbollah, Iran) pose risks to operations, supply chains, and employee availability (military reserve call-ups), though management states no material impact to date.
- B2B Licensing: The company has not yet signed a commercial license agreement with any B2B customer. The sales cycle is estimated at 3-5 years.
- Government Grants: The company has contingent liabilities of approximately $2.4 million related to royalties owed to the Israeli Innovation Authority (IIA) based on future sales of funded products.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.1 million cash balance to fund operations through the projected September 2025 date, considering the high burn rate.
- Nasdaq Status: Monitor the status of the plan to regain compliance with the $2.5 million stockholders' equity requirement to avoid delisting.
- B2B Pipeline: Assess the progress of the 100+ B2B customers who have purchased development kits; confirm if any have moved toward signing commercial license agreements.
- Geopolitical Exposure: Review updates on the impact of the conflict in Israel on manufacturing, supply chain logistics, and employee availability.
- Grant Obligations: Understand the terms of the IIA grants and the potential cash outflow for royalties (3-3.5% of sales) as revenue scales.